Ashling Wahner

Bendamustine plus obinutuzumab outperformed historical data of bendamustine plus rituximab for patients with treatment naïve mantle cell lymphoma.

The FDA granted namodenoson an orphan drug designation for patients who have pancreatic cancer.

Belantamab mafodotin plus KRd had a a manageable safety profile and deep responses in pretreated multiple myeloma.

Fast track designation has been granted by the FDA to Deltacel with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Compared with chemotherapy, enfortumab vedotin plus pembrolizumab improved survival with no detriment to QOL in previously untreated metastatic urothelial cancer.

Nivolumab plus tivozanib did not improve progression-free survival in patients with advanced metastatic renal cell carcinoma after prior immune checkpoint inhibition.

Fast track designation has been awarded by the FDA to the next-generation precision radiopharmaceutical therapy ABD-147 to treat extensive-stage small cell lung cancer.

The progression-free survival benefit with belzutifan was observed across subgroups of patients with pretreated advanced clear cell renal cell carcinoma.

A fixed-duration treatment combining acalabrutinib and venetoclax, with or without obinutuzumab, significantly extended progression-free survival in patients with previously untreated chronic lymphocytic leukemia.

Final results of the ARMANI trial demonstrated that switch maintenance therapy with ramucirumab plus paclitaxel improved survival in advanced HER2-negative gastric or gastroesophageal junction cancer.

Progression-free survival and platinum chemoresistance may be predicted by tumor-stroma proportion in patients with high-grade serous ovarian cancer.

Monotherapy with IBI343 received fast track designation from the FDA for advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Compared with epoetin alfa, treatment with luspatercept improved erythroid response rates and the duration of transfusion independence for lower-risk myelodysplastic syndromes.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dostarlimab plus chemotherapy has been granted priority review from the FDA to expand its indication to all adult patients with primary advanced or recurrent endometrial cancer.

Patients with chronic graft-vs-host disease treated with belumosudil experienced responses out to 3 years with no new safety signals.

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Patients with renal cell carcinoma who did not undergo surgical resection and were treated with stereotactic ablative body radiotherapy experienced high local control rates with an acceptable side effect profile.

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

Patients with hematologic malignancies who received Orca-T improved survival rates compared with PTCy in those receiving myeloablative conditioning, according to findings from a retrospective analysis.

Ropeginterferon alfa-2b has been listed as a preferred first-line cytoreductive therapy by the National Comprehensive Cancer Network for patients with polycythemia vera.

Patients with stage III epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery had improved progression-free survival and overall survival.

A priority review has been granted by the FDA to trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2-positive advanced solid tumors.

Treatment with asciminib for newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase induced statistically significant and clinically meaningful major molecular response benefits compared with standard-of-care TKIs.

A disease-free survival benefit continued with adjuvant pembrolizumab when compared with placebo in patients with resected early-stage NSCLC.

Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.

Brexucabtagene autoleucel was associated with a 91% overall response rate among patients with relapsed/refractory mantle cell lymphoma.

The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.

There have been reports of T-cell malignancies among patients who have undergone CD19- or BCMA-directed autologous CAR T-cell immunotherapies.